R&D Trends

Seattle Genetics, Abbott expand antibody-drug conjugate collaboration

Wednesday, October 24, 2012 11:02 AM

Seattle Genetics, a Bothell, Wash.-based biotech focused on monoclonal antibody-based therapies for the treatment of cancer, has expanded its antibody-drug conjugate (ADC) collaboration with Abbott Laboratories, a global healthcare company.

More... »

PFF calls for letters of intent for 2013 Young Investigator and Established Investigator awards

Wednesday, October 24, 2012 10:11 AM

The Pulmonary Fibrosis Foundation (PFF) is accepting letters of intent for its 2013 PFF Research Fund grants.  Letters of intent will be accepted until Monday, November 26.  

More... »

Cortex unveils growth plans, 1,400 new jobs

Wednesday, October 24, 2012 09:24 AM

Cortex, a St. Louis-based hub of bioscience and technology R&D and commercialization, has unveiled phase two of its 25-year master plan, which will bring 1,400 new jobs and 384,000 square feet of additional lab and office space to the district.

More... »

Catalent Pharma launches Catalent Applied Drug Delivery Institute

Monday, October 22, 2012 11:38 AM

Catalent Pharma Solutions, a developer of solutions and advanced drug delivery technologies, has launched its Catalent Applied Drug Delivery Institute.

More... »

Venture capital investments decline in dollars and deal volume in Q3 2012

Friday, October 19, 2012 03:26 PM

Venture capitalists invested $6.5 billion in 890 deals in the third quarter of 2012, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

More... »

Longitude Capital closes second life sciences fund with $385M

Friday, October 12, 2012 12:13 PM

Longitude Capital has closed the Longitude Venture Partners II, a $385 million venture capital fund dedicated to investments in drug development and medical technology. 

More... »

GSK announces initiatives to advance openness and collaboration for global health challenges

Friday, October 12, 2012 11:04 AM

Global healthcare company GlaxoSmithKline has announced new measures to further advance its commitment towards greater openness, transparency and collaboration, designed to help develop new solutions for the world’s most serious health challenges.

More... »

Sanofi, Mass. General Hospital launch oncology research collaboration

Thursday, October 11, 2012 07:00 AM

Global healthcare company Sanofi has formed a two-year agreement with Massachusetts General Hospital (MGH) aimed at furthering translational medicine research to develop new treatments for various types of hematological malignancies and solid tumors.

More... »

Investigational drugs chosen for major Alzheimer's prevention trial

Thursday, October 11, 2012 07:00 AM

Scientists have selected the first investigational drugs for a worldwide Alzheimer's disease prevention trial. The pioneering study, expected to start by early 2013, initially will test three promising drugs—gantenerumab, solanezumab and an unnamed BACE inhibitor—each designed to target Alzheimer's in different ways.

More... »

Roche, Versant, Inception pursue novel treatments for sensorineural hearing loss

Wednesday, October 10, 2012 02:03 PM

Roche has entered into an exclusive partnership with Versant Ventures,  healthcare venture capital firm based in Menlo Park, Calif., and Inception Sciences, a San Diego-based drug discovery company, to create a drug discovery incubator, Inception 3, for the treatment of sensorineural hearing loss.

More... »